Phosphatidylserine / DHA Cancer Research Results

PS, Phosphatidylserine: Click to Expand ⟱
Features:

Phosphatidylserine (PS) — an anionic membrane phospholipid (glycerophospholipid) enriched in brain and inner-leaflet plasma membranes. Supplement sources: soy-derived PS (modern) and historically bovine cortex PS (largely discontinued in many markets).

Primary mechanisms (conceptual rank):
1) Membrane signaling scaffold (protein kinase docking; synaptic membrane function)
2) Apoptotic “eat-me” signal when externalized (PS flip to outer leaflet) → immunologic clearance axis
3) Stress-axis modulation (HPA/cortisol context; cognitive-stress performance literature)
4) Neurotransmission support (cholinergic/synaptic plasticity coupling; indirect)

Bioavailability / PK relevance: Oral PS is digested to lyso-phospholipids/fatty acids and re-esterified; effects are typically chronic (weeks) and reflect membrane remodeling and signaling adaptation rather than acute pharmacology.

In-vitro vs oral exposure: Direct anti-cancer cytotoxicity from PS exposure is generally not a physiologic oral-supplement mechanism; many tumor-PS findings relate to surface PS biology and targeting strategies rather than dietary PS.

Clinical evidence status: Human data strongest for cognitive/stress outcomes (modest; mixed by age/product/dose). Oncology relevance is mainly mechanistic/targeting-adjacent (preclinical).

PS is a negatively charged phospholipid found predominantly in the inner leaflet of cell membranes, especially in neurons.
-Clinical trials show potential benefits in:
-Improving memory and attention in elderly subjects
-Slowing cognitive decline in early AD or mild cognitive impairment (MCI)
-PS is thought to enhance cell membrane function, neurotransmission, and possibly reduce oxidative stress.


Phosphatidylserine (PS) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PS externalization (apoptotic / tumor-surface PS) ↑ surface PS (context-dependent) ↑ during apoptosis P/R Immune recognition / clearance cue Many tumors display elevated outer-leaflet PS (often due to stress, hypoxia, ROS, therapy); key for PS-targeting strategies (antibodies/ligands), not necessarily oral PS.
2 Tumor immune microenvironment (PS-mediated immunosuppression) ↑ immunosuppressive signaling (context-dependent) ↔ R/G “Quiet” clearance phenotype Outer PS can bias toward tolerogenic phagocytosis (TAMs/MDSCs) and reduced anti-tumor immunity (model-dependent).
3 Membrane signaling scaffold (PKC/AKT docking; lipid rafts) ↔ / ↑ (context-dependent) ↑ physiologic signaling support G Signal transduction modulation PS provides anionic docking sites for kinases; in cancer this can support survival signaling depending on pathway context.
4 Apoptosis execution (intrinsic pathway) ↑ (secondary to stress/therapy) ↑ R/G Cell death progression PS is a marker and mediator of apoptotic clearance rather than a primary trigger from supplementation.
5 ROS ↑ → PS flip (context-dependent) ↑ → PS flip (high stress) P/R Oxidative stress coupling ROS and lipid peroxidation can promote membrane asymmetry loss and PS externalization.
6 NRF2 axis ↔ ↔ R/G No primary modulation PS is not a canonical NRF2 modulator; any linkage is indirect via oxidative stress state.
7 Ferroptosis (membrane lipid peroxidation) ↔ / ↑ PS flip (secondary) ↔ R/G Peroxidation-driven membrane stress Not a primary PS mechanism; lipid peroxidation can destabilize membrane asymmetry and expose PS.
8 HIF-1α / hypoxia stress coupling ↑ surface PS (hypoxia-linked; context-dependent) ↔ G Stress phenotype marker Hypoxia/therapy stress can increase tumor-surface PS; largely a state-marker and targetable feature.
9 Ca²⁺-dependent scramblase / flippase balance ↑ PS externalization (stress-dependent) ↑ PS externalization (stress-dependent) P/R Membrane asymmetry regulation Elevated intracellular Ca²⁺ activates scramblases and can promote PS exposure; relevant in apoptosis/ER stress models.
10 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Supplement vs targeting mismatch Oral PS mainly supports normal-cell membrane/synaptic function; oncology relevance is primarily via tumor-surface PS targeting, not dietary PS delivery.

TSF legend:
P: 0–30 min (membrane asymmetry/ion effects)
R: 30 min–3 hr (stress signaling + apoptosis progression)
G: >3 hr (membrane remodeling / phenotype outcomes)


Phosphatidylserine (PS) — AD relevance: A brain-enriched phospholipid linked to synaptic membrane function and signaling; supplementation is used for cognitive symptoms and stress-related memory performance. AD/MCI relevance is mainly supportive (synaptic function + stress-axis), not disease-modifying.

Primary mechanisms (conceptual rank):
1) ↑ Synaptic membrane function / signaling efficiency (plasticity support)
2) ↓ Stress-axis overactivation (cortisol/HPA modulation; context-dependent)
3) ↑ Cholinergic neurotransmission support (indirect)
4) ↓ Neuroinflammation / oxidative burden (secondary; modest evidence)

Bioavailability / PK relevance: Effects typically require weeks of daily intake (remodeling/adaptation). Outcomes depend on dose, source, baseline diet, and cognitive status.

Clinical evidence status: Small human trials show modest benefits in some groups (older adults, stress-related impairment, MCI signals); overall mixed and not definitive for AD progression.

Phosphatidylserine (PS) — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 Synaptic membrane function / plasticity ↑ G Improved signaling efficiency PS supports membrane microdomains and protein docking needed for synaptic transmission; benefits are typically chronic/adaptive.
2 Stress-axis (HPA/cortisol) ↓ (context-dependent) R/G Reduced stress-related cognitive impairment Best described in stress-performance contexts; relevance to AD depends on stress burden and comorbidity.
3 Cholinergic signaling ↑ (indirect) R/G Neurotransmission support Supportive mechanism; not equivalent to AChE inhibitor pharmacology.
4 ROS ↔ / ↓ (secondary) P/R Oxidative burden moderation Not a primary antioxidant; effects are indirect via improved membrane/mitochondrial resilience.
5 NRF2 axis ↔ R/G No primary modulation Any NRF2 linkage is indirect and model-dependent.
6 Neuroinflammation ↔ / ↓ (secondary) R/G Inflammatory tone modulation Reported in some models; generally not the dominant mechanism for PS supplementation.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ / stabilized (indirect) P/R Membrane/ion-channel environment support Membrane composition can influence channel/receptor function; treat as secondary unless specific Ca²⁺ data exist.
8 Aβ / tau pathology ↔ (limited evidence) G Not primary axis PS is not established to directly reduce amyloid/tau burden in humans.
9 Clinical Translation Constraint ↓ (constraint) — Modest, non–disease-modifying Benefits (when present) are modest and require sustained dosing; product source/dose and baseline status drive variability.

TSF legend:
P: 0–30 min (membrane/ion interactions)
R: 30 min–3 hr (acute signaling shifts)
G: >3 hr (remodeling/adaptation outcomes)
DHA, docosahexaenoic acid: Click to Expand ⟱
Source:
Type:
DHA (docosahexaenoic acid; 22:6 n-3) is a long-chain omega-3 polyunsaturated fatty acid that functions less like a single “pathway enzyme” and more like a systems-level lipid signaling axis. Most commonly reported directions (context-dependent by dose, formulation, and tumor type):
-↑ Lipid peroxidation → ↑ ferroptosis susceptibility (anti-tumor)
DHA can increase lipid peroxides and promote ferroptotic tumor cell death in some models.
-↓ Proliferation / ↑ apoptosis (anti-tumor tendency)
Reviews summarize inhibition of growth and invasion and pro-apoptotic signaling across multiple cancers (heterogeneous evidence quality; not a universal effect).
Inflammation/eicosanoid “tilt” toward resolution
By shifting lipid mediator balance away from arachidonic-acid–derived pro-inflammatory mediators and toward SPMs, DHA can reduce pro-tumor inflammatory signaling in some contexts.
Big caveat: because DHA can drive oxidative lipid damage, the net effect depends heavily on antioxidant defenses (e.g., GPX4/GSH), iron handling, and whether the tumor is ferroptosis-sensitive.
Effects in Alzheimer’s disease (AD) and neurodegeneration

Mechanistically, DHA is highly relevant to brain biology, but clinical outcomes depend on disease stage:
-Structural/synaptic support (membrane axis)
DHA is a major brain omega-3 and supports membrane properties linked to synaptic function.
-↑ Pro-resolving lipid mediators → microglia modulation / inflammation resolution
SPMs derived from DHA are discussed as supporting a “pro-resolution” microglial phenotype and potentially improving amyloid handling (mechanistic/biomarker-level rationale).
-Clinical signal: more promising earlier (MCI) than established AD A 2023 review notes DHA supplementation shows benefit in some RCTs for mild cognitive impairment (MCI), but no consistent benefit in diagnosed Alzheimer’s disease.
A 2025 meta-analysis in AD similarly concludes omega-3 supplementation does not significantly improve cognition in adults with AD.
Scientific Papers found: Click to Expand⟱
6879- PS,  aLinA,    Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial
- Trial, Nor, NA
*Dose↝, *cognitive↑, *memory↑, *DHA↑, *EP2↑, *Ach↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

DHA↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EP2↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 1,   memory↑, 1,  
Total Targets: 6

Scientific Paper Hit Count for: DHA, docosahexaenoic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:341  Target#:1379  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page